Quick Answer
Mineralys Therapeutics, Inc. reported Cash and Equivalents of $172.92 million for fiscal year 2025.
Mineralys Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $172.92M | +51.6% |
| 2024 | $114.09M | +131.4% |
| 2023 | $49.30M | -43.8% |
| 2022 | $87.70M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $217.60M | +123.7% | +113.8% |
| June 30, 2025 | $101.79M | +50.0% | -38.3% |
| March 31, 2025 | $165.01M | +82.5% | +44.6% |
| December 31, 2024 | $114.09M | +131.4% | +17.3% |
| September 30, 2024 | $97.27M | +12.7% | +43.4% |
| June 30, 2024 | $67.86M | -32.9% | -25.0% |
| March 31, 2024 | $90.42M | -34.6% | +83.4% |
| December 31, 2023 | $49.30M | -43.8% | -42.9% |
- Mineralys Therapeutics, Inc. showed an increase of +51.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Mineralys Therapeutics, Inc.’s cash and equivalents has grown by 97.2% (from $87.70 million to $172.92 million).
- The most recent figure is from Mineralys Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: